Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases

Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Helge H O, Moeller, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055274/
https://www.ncbi.nlm.nih.gov/pubmed/33883898
http://dx.doi.org/10.2147/NDT.S303817
_version_ 1783680420202676224
author Müller, Helge H O
Moeller, Sebastian
author_facet Müller, Helge H O
Moeller, Sebastian
author_sort Müller, Helge H O
collection PubMed
description Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients with weight management problems. In this case series, two cases and the outcomes during the switch to cariprazine treatment under these conditions are described.
format Online
Article
Text
id pubmed-8055274
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80552742021-04-20 Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases Müller, Helge H O Moeller, Sebastian Neuropsychiatr Dis Treat Case Series Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients with weight management problems. In this case series, two cases and the outcomes during the switch to cariprazine treatment under these conditions are described. Dove 2021-04-15 /pmc/articles/PMC8055274/ /pubmed/33883898 http://dx.doi.org/10.2147/NDT.S303817 Text en © 2021 Müller and Moeller. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Müller, Helge H O
Moeller, Sebastian
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_full Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_fullStr Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_full_unstemmed Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_short Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
title_sort decline in psychotic symptoms in addition to cardiac and metabolic safety with cariprazine after poor response to previous antipsychotic treatments – a series of two cases
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055274/
https://www.ncbi.nlm.nih.gov/pubmed/33883898
http://dx.doi.org/10.2147/NDT.S303817
work_keys_str_mv AT mullerhelgeho declineinpsychoticsymptomsinadditiontocardiacandmetabolicsafetywithcariprazineafterpoorresponsetopreviousantipsychotictreatmentsaseriesoftwocases
AT moellersebastian declineinpsychoticsymptomsinadditiontocardiacandmetabolicsafetywithcariprazineafterpoorresponsetopreviousantipsychotictreatmentsaseriesoftwocases

Ejemplares similares